(RTTNews) - BioNTech SE (BNTX) said that preliminary phase 1 results from Lipo-MERIT trial with data from 89 patients highlight favorable tolerability profile of BNT111 in advanced melanoma patients. The company noted that efficacy analysis in a subset of 42 checkpoint-inhibitor (CPI)-experienced metastatic melanoma patients showed that BNT111 mediates durable responses both as a single agent and in combination with anti-PD-1 antibodies. BioNTech's FixVac platform candidates consist of a fixed combination of mRNA-encoded non-mutated antigens shared within specific cancer types.